Pulmonary function decreases moderately after accelerated high‐dose irradiation for stage III non‐small cell lung cancer

Autor: Romana Wass, Christian Pirich, Felix Sedlmayer, Julia Kaiser, Frank Wolf, Christoph Gaisberger, Michael Studnicka, Lukas Rettenbacher, Gerd Fastner, Franz Zehentmayr, Brane Grambozov
Rok vydání: 2019
Předmět:
Male
0301 basic medicine
Lung Neoplasms
minimal clinically important difference (MCID)
NSCLC
Pulmonary function testing
FEV1
0302 clinical medicine
DLCO
Carcinoma
Non-Small-Cell Lung
Diffusing capacity
Lung
Aged
80 and over
COPD
Minimal clinically important difference
Standard treatment
Radiotherapy Dosage
General Medicine
Middle Aged
respiratory system
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Prognosis
Respiratory Function Tests
Survival Rate
medicine.anatomical_structure
Oncology
030220 oncology & carcinogenesis
Original Article
Female
Adult
Pulmonary and Respiratory Medicine
medicine.medical_specialty
Urology
lcsh:RC254-282
03 medical and health sciences
medicine
Humans
radiotherapy
Aged
business.industry
Original Articles
medicine.disease
respiratory tract diseases
030104 developmental biology
Radiotherapy
Intensity-Modulated
business
Chemoradiotherapy
Follow-Up Studies
Zdroj: Thoracic Cancer
Thoracic Cancer, Vol 11, Iss 2, Pp 369-378 (2020)
ISSN: 1759-7714
1759-7706
Popis: Background Chemoradiotherapy (CRT) is the standard treatment for patients with inoperable stage III non‐small cell lung cancer (NSCLC) stage III. With a median OS beyond 30 months, adequate pulmonary function (PF) is essential to ensure acceptable quality of life after treatment. Forced expiratory volume in 1 second (FEV1) and diffusing capacity of the lung for carbon monoxide (DLCO) are the most widely used parameters to assess lung function. The aim of the current study was to evaluate dose‐volume effects of accelerated high‐dose radiation on PF. Methods A total of 72 patients were eligible for the current analysis. After induction chemotherapy, all patients received dose‐differentiated accelerated radiotherapy with intensity‐modulated radiotherapy (IMRT‐DART). PF tests were performed six weeks, three and six months after the end of radiotherapy. Results The median total dose to the tumor was 73.8 Gy (1.8 Gy bid) with a size dependent range between 61.2 and 90 Gy. In the whole cohort, 321 pulmonary function tests were performed. At six months, the median FEV1 relative to baseline was 0.95 (range: 0.56–1.36), and the relative median DLCO decreased to 0.98 (range: 0.64–1.50). The correlation between V20total lung and FEV1 decline was statistically significant (P = 0.023). A total of 13 of 34 (38%) COPD patients had a 4%–21% FEV1 decrease. Conclusion Patients with a V20total lung
Databáze: OpenAIRE
Externí odkaz: